Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283980 · ClinicalTrials.gov registry record · Phase 2
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
A Phase 2 study of Pain and Pain, Postoperative, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT05283980: Active Phase 2 study of Pain and Pain, Postoperative, sponsored by Beth Israel Deaconess Medical Center.
NCT05283980 is a Phase 2 study of Pain and Pain, Postoperative that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 62 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283980, a Phase 2 study of Pain and Pain, Postoperative, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether administration of a pectoral nerve blocks (Pecs I and II) with 0.25% bupivacaine are more effective as compared to placebo to provide analgesia for cardiac implantable electronic device (CIED) placement in cardiac electrophysiology lab
Primary Outcome
peri-operative 24-hour consumption of opioids measured as OMEs (Opioid milliequivalents) in patients undergoing CIED procedures with and without Pecs blocks
Conditions Studied
Interventions
- DRUG 0.25% Bupivacaine
Study Locations (1)
Massachusetts
- BIDMC - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2025-03 |
| Phase | Phase 2 |
What the registry record for NCT05283980 still lists
NCT05283980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (80% lower).
The record links to 7 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which 0.25% Bupivacaine is the first listed.
NCT05283980 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05283980 about?
NCT05283980 is a clinical study titled "Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement". The purpose of this study is to determine whether administration of a pectoral nerve blocks (Pecs I and II) with 0.25% bupivacaine are more effective as compared to placebo to provide analgesia for cardiac implantable electronic device (CIED) placement in cardiac electrophysiology lab
What is the current status of trial NCT05283980?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2022-11-17. Estimated completion is 2025-03.
What conditions does trial NCT05283980 study?
This clinical trial studies the following conditions: Pain, Pain, Postoperative, Pain, Acute, Opioid Use, Unspecified, Satisfaction, Patient.
What interventions are being tested in trial NCT05283980?
The interventions under investigation include: 0.25% Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT05283980?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283980 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05283980's enrollment target sits among peer trials
62 223rd of 374 higher than 152 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI